Oral neratinib: Phase II data

Data from 14 heavily pretreated patients with HER2-mutant, non-amplified metastatic breast cancer in a 2-part, open-label, U.S. and Canadian Phase II trial showed that once-daily 240 mg oral neratinib met the primary endpoint in the

Read the full 353 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE